

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085253 A1

- (51) International Patent Classification: **C07D 487/04**,
A61K 31/505
- (21) International Application Number:
PCT/JP2005/004266
- (22) International Filing Date: 4 March 2005 (04.03.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2004-061555 5 March 2004 (05.03.2004) JP
- (71) Applicant (for all designated States except US): **TAISHO PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo 1708633 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BISCHOFF, Francois, P.** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KENNIS, Ludo, E., J.** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BRAEKEN, Mirielle** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **DIELS, Gaston, S., M.** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **NAKAZATO, Atsuro** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo 1708633 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRROLOPYRIMIDINE DERIVATIVES



[I]

(57) Abstract: According to the present invention, there is provided an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitis, schizophrenia, pain, etc. A pyrrolopyrimidine derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

DESCRIPTION

PYRROLOPYRIMIDINE DERIVATIVES

TECHNICAL FIELD

The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.

DESCRIPTION OF THE PRIOR ART

CRF is a hormone comprising 41 amino acids (Science, 213, 1394-1397, 1981; and J. Neurosci., 7, 88-100, 1987), and it is suggested that CRF plays a core role in biological reactions against stresses (Cell. Mol. Neurobiol., 14, 579-588, 1994; Endocrinol., 132, 723-728, 1994; and Neuroendocrinol. 61, 445-452, 1995). For CRF, there are the following two paths: a path by which CRF acts on peripheral immune system or sympathetic nervous system through hypothalamus-pituitary-adrenal system, and a path by which CRF functions as a neurotransmitter in central nervous system (in Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide, pp. 29-52, 1990). Intraventricular administration of CRF to hypophysectomized rats and normal rats causes an anxiety-like symptom in both types of rats (Pharmacol. Rev., 43, 425-473, 1991; and Brain Res. Rev., 15, 71-100, 1990). That is, there are suggested the participation of CRF in hypothalamus-pituitary-adrenal system and the pathway by which CRF functions as a neurotransmitter in central nervous system.

The review by Owens and Nemeroff in 1991 summarizes diseases in which CRF is involved (Pharmacol. Rev., 43, 425-474, 1991). That is, CRF is involved in depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug

dependence, inflammation, immunity-related diseases, etc. It has recently been reported that CRF is involved also in epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, and cephalic external wound (Brain Res. 545, 339-342, 1991; Ann. Neurol. 31, 48-498, 1992; Dev. Brain Res. 91, 245-251, 1996; and Brain Res. 744, 166-170, 1997). Accordingly, antagonists against CRF receptors are useful as therapeutic agents for the diseases described above.

US2004224964 discloses 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine derivatives as CRF receptor antagonists. However, none disclose the compounds provided in the present invention.


10 PROBLEM(S) TO BE SOLVED BY THE INVENTION

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.

MEANS FOR SOLVING THE PROBLEM

The present inventors earnestly investigated pyrrolopyrimidines that have a high affinity for CRF receptors, whereby the present invention has been accomplished.

The present invention is pyrrolopyrimidine derivatives explained below. A pyrrolopyrimidine derivative represented by the following formula [I]:



3

- (wherein R¹ is C₁₋₉alkyl, C₂₋₉alkenyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₉alkyl, di(C₃₋₇cycloalkyl)-C₁₋₉alkyl, C₁₋₆alkoxy-C₁₋₉alkyl, di(C₁₋₆alkoxy)-C₁₋₉alkyl, hydroxy-C₁₋₉alkyl, cyano-C₁₋₉alkyl, carbamoyl-C₁₋₉alkyl, di(C₁₋₆alkyl)amino-C₁₋₉alkyl, aryl, heteroaryl, aryl-C₁₋₉alkyl or heteroaryl-C₁₋₉alkyl, in which said aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, halogen, C₁₋₆haloalkyl, cyano, nitro, -NR^{1a}R^{1b}, where R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₆alkyl and C₁₋₆alkylcarbonyl;
- R² is C₁₋₆alkyl or C₁₋₆haloalkyl;
- R³ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, benzyl;
- the bond between X and Y is a single bond or a double bond;
- wherein (1) when the bond between X and Y is a single bond, X is CR⁴R⁵ or C=O; Y is CR⁶R⁷, C=O, C=N-OR⁸ or C=CH-R⁹; (2) when the bond between X and Y is a double bond, X is CR¹⁰; Y is CR¹¹;
- R⁴ and R⁵ are the same or different, and independently are hydrogen or C₁₋₆alkyl;
- R⁶ and R⁷ are the same or different, and independently are hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, hydroxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino-C₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₃₋₆cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, C₁₋₆alkylaminocarbonyl or C₁₋₆alkylaminocarbonylamino; or R⁶ and R⁷ are taken together to form C₃₋₆cycloalkyl, with the proviso that not both of CR⁴R⁵ and CR⁶R⁷ are CH₂;
- R⁸ is hydrogen or C₁₋₆alkyl;
- R⁹ is C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen or C₁₋₆alkyl;
- R¹⁰ is hydrogen or C₁₋₆alkyl;
- R¹¹ is hydrogen, C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl;
- Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or

- substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, cyano, C₁₋₆haloalkyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

The terms used in the present specification have the following meanings.

- 10 The term "C₁₋₉alkyl" means a straight chain or branched chain alkyl group of 1 to 9 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *tert*-butyl, *sec*-butyl, pentyl, isopentyl, 1-methylbutyl, hexyl, isohexyl, 1-ethylpropyl, 1-ethylbutyl, 1,3-dimethylbutyl, 1-propylbutyl, 1-propylpentyl, 1-butylpentyl or the like.
- 15 The term "C₂₋₉alkenyl" means a straight chain or branched chain alkenyl group of 2 to 9 carbon atoms, such as vinyl, isopropenyl, allyl or the like.
- The term "C₃₋₇cycloalkyl" means a cyclic alkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like.
- 20 The term "C₃₋₇cycloalkyl-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having the above-mentioned C₃₋₇cycloalkyl as the substituent, such as cyclopropylmethyl, 1-cyclopropylethyl, 1-cyclobutylethyl, 1-cyclopentylethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, 1-cyclopropylpropyl, 1-cyclobutylpropyl, 1-cyclopentylpropyl, 1-cyclopropylmethylpropyl, 1-cyclopropylmethylbutyl or the like.

The term "di(C₃₋₇cycloalkyl)-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having two above-mentioned C₃₋₇cycloalkyl groups as the substituents, such as di(cyclopropyl)methyl, di(cyclobutyl)methyl, di(cyclopentyl)methyl or the like.

- 30 The term "C₁₋₆alkoxy" means a straight chain or branched chain alkoxy group of 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentyloxy, isopentyloxy or the like.

The term "C₁₋₆alkoxy-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having the above-mentioned C₁₋₆alkoxy group as the substituent, such as

methoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, 1-methoxymethyl-propyl, 1-methoxymethyl-butyl or the like.

The term "di(C₁₋₆alkoxy)-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having two above-mentioned C₁₋₆alkoxy groups as the substituents, such as 2,3-di(methoxy)propyl, 2-methoxy-1-methoxymethyl-ethyl, 2,4-(diethoxy)pentyl or the like.

The term "hydroxy-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having a hydroxy group, such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 1-hydroxymethyl-propyl, 1-hydroxymethyl-butyl, 1-hydroxymethyl-3-methyl-butyl or the like.

The term "cyano-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having a cyano group, such as cyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 1-cyanopropyl, 1-cyanobutyl, 5-cyanopentyl, 2-cyano-1-ethyl-ethyl, 1-cyanomethyl-butyl, 1-cyano-3-methyl-butyl, 1-cyanomethyl-3-methyl-butyl or the like.

The term "carbamoyl-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having a carbamoyl group, such as carbamoylmethyl, 1-carbamoyl-ethyl, 2-carbamoyl-ethyl, 1-carbamoyl-propyl, 1-carbamoyl-butyl, 5-carbamoyl-pentyl, 1-carbamoyl-3-methyl-butyl, 1-carbamoyl-methyl-butyl, 1-carbamoylmethyl-propyl, 1-carbamoylmethyl-3-methyl-butyl or the like.

The term "di(C₁₋₆alkyl)amino" means an amino group having two above-mentioned C₁₋₆alkyl groups, such as dimethylamino, diethylamino, dipropylamino or the like.

The term "di(C₁₋₆alkyl)amino-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having an above-mentioned di(C₁₋₆alkyl)amino group, such as 2-dimethylaminoethyl, 3-dimethylaminopropyl or the like.

The term "aryl" means a monocyclic or bicyclic group of 6 to 12 ring carbon atoms having at least one aromatic ring, such as phenyl, naphthyl, or the like.

The term "heteroaryl" means a monocyclic or bicyclic group of 5 to 12 ring atoms having at least one aromatic ring having in its ring 1 to 4 atoms which may be the same or different and are selected from nitrogen, oxygen and sulfur, such as pyridyl, pyrimidinyl, imidazolyl, furyl, thienyl, quinolyl, indolyl,

benzofuranyl, quinoxalanyl, benzo[1,2,5]thiadiazolyl, benzo[1,2,5]oxadiazolyl or the like.

The term "aryl-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having an above-mentioned aryl group, such as benzyl, phenethyl, 3-phenylpropyl or the like.

5 The term "heteroaryl-C₁₋₉alkyl" means a substituted C₁₋₉alkyl group having an above-mentioned heteroaryl group, such as pyridin-2-ylmethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl or the like.

The term "C₁₋₆alkylthio" means a straight chain or branched chain alkylthio group of 1 to 6 carbon atoms, such as methylthio, ethylthio, propylthio or
10 the like.

The term "C₁₋₆alkylsulfonyl" means a straight chain or branched chain alkylsulfonyl group of 1 to 6 carbon atoms, such as methylsulfonyl, ethylsulfonyl, propylsulfonyl or the like.

The term "mono(C₁₋₆alkyl)aminosulfonyl" means a substituted
15 aminosulfonyl group having an above mentioned C₁₋₆alkyl, such as methylaminosulfonyl, ethylaminosulfonyl or the like.

The term "di(C₁₋₆alkyl)aminosulfonyl" means a substituted aminosulfonyl group having two above mentioned C₁₋₆alkyl, such as dimethylaminosulfonyl, diethylaminosulfonyl or the like.

20 The term "halogen" means fluorine, chlorine, bromine or iodine atom.

The term "C₁₋₆haloalkyl" means a substituted C₁₋₆alkyl having one to three halogen atoms, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl or the like.

The term "C₁₋₆alkylcarbonyl" means an acyl group of 1 to 7 carbon atoms
25 acetyl, propionyl, butyryl or the like.

The term "C₂₋₆alkynyl" means a straight chain or branched chain alkynyl group of 2 to 6 carbon atoms, such as ethynyl, prop-1-ynyl, prop-2-ynyl or the like.

The term "C₁₋₆alkylamino" means a substituted amino group having an above-mentioned C₁₋₆alkyl group, such as methylamino, ethylamino, propylamino
30 or the like.

The term "C₁₋₆alkylcarbonylamino" means a substituted amino group having a C₁₋₆alkylcarbonyl group, such as acetylamino, propionylamino, 3-methylbutyrylamino, isobutyrylamino, *n*-butyrylamino or the like.

The term "C₃₋₆cycloalkylcarbonylamino" means a substituted amino group having a C₃₋₆cycloalkylcarbonyl group, such as cyclopropanecarbonylamino, cyclobutanecarbonylamino, cyclopentanecarbonylamino or the like.

The term "arylcarbonylamino" means a substituted amino group having an above mentioned aryl group, such as phenylcarbonylamino or the like.

The term "heteroarylcarbonylamino" means a substituted amino group having an above mentioned heteroaryl group, such as (furan-2-carbonyl)amino, (pyridine-2-carbonyl)amino, (pyridine-3-carbonyl)amino, (pyridine-4-carbonyl)amino or the like.

The term "C₁₋₆alkylaminocarbonyl" means a substituted aminocarbonyl group having an above mentioned C₁₋₆alkyl group, such as methylcarbamoyl, ethylcarbamoyl, isopropylcarbamoyl or the like.

The term "C₁₋₆alkylaminocarbonylamino" means a substituted aminocarbonylamino group having an above mentioned C₁₋₆alkyl group, such as 3-methylureido, 3-ethylureido, 3-propylureido, 3-isopropylureido or the like.

The phrase "aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, cyano, C₁₋₆haloalkyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl" includes, for example, 2,4-dimethylphenyl, 2,6-dimethylphenyl, 2,4-dibromophenyl, 2-bromo-4-isopropylphenyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 2-chloro-4-trifluoromethylphenyl, 4-methoxy-2-methylphenyl, 2-chloro-4-trifluoromethoxyphenyl, 4-isopropyl-2-methylthiophenyl, 2,4,6-trimethylphenyl, 4-bromo-2,6-dimethylphenyl, 4-bromo-2,6-diethylphenyl, 4-chloro-2,6-dimethylphenyl, 2,4,6-tribromophenyl, 2,4,5-tribromophenyl, 2,4,6-trichlorophenyl, 2,4,5-trichlorophenyl, 4-bromo-2,6-dichlorophenyl, 6-chloro-2,4-dibromophenyl, 2,4-dibromo-6-fluorophenyl, 2,4-dibromo-6-methylphenyl, 2,4-dibromo-6-methoxyphenyl, 2,4-dibromo-6-methylthiophenyl, 2,6-dibromo-4-isopropylphenyl, 2,6-dibromo-4-trifluoromethylphenyl, 2-bromo-4-trifluoromethylphenyl, 4-bromo-2-chlorophenyl, 2-bromo-4-chlorophenyl, 4-bromo-2-methylphenyl, 4-chloro-2-


- methylphenyl, 2,4-dimethoxyphenyl, 2,6-dimethyl-4-methoxyphenyl, 4-chloro-2,6-dibromophenyl, 4-bromo-2,6-difluorophenyl, 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-trifluoromethoxyphenyl, 2,6-dibromo-4-trifluoromethoxyphenyl, 2-chloro-4,6-dimethylphenyl, 2-bromo-4,6-dimethoxyphenyl, 2-bromo-4-isopropyl-6-methoxyphenyl, 2,4-dimethoxy-6-methylphenyl, 6-dimethylamino-4-methylpyridin-3-yl, 2-chloro-6-trifluoromethylpyridin-3-yl, 2-chloro-6-trifluoromethoxypyridin-3-yl, 2-chloro-6-methoxypyridin-3-yl, 6-methoxy-2-trifluoromethylpyridin-3-yl, 2-chloro-6-difluoromethylpyridin-3-yl, 6-methoxy-2-methylpyridin-3-yl, 2,6-dimethoxypyridin-3-yl, 4,6-dimethyl-2-trifluoromethylpyrimidin-5-yl, 2-dimethylamino-6-methylpyridin-3-yl.

The "pharmaceutically acceptable salts" in the present invention include, for example, salts with an inorganic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or the like; salts with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, *p*-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like; salts with one or more metal ions such as lithium ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, aluminium ion or the like; salts with an amine such as ammonia, arginine, lysine, piperazine, choline, diethylamine, 4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like.

In a compound of the present invention, isomers such as diastereomers, enantiomers, geometric isomers and tautomeric forms may exist. The compound of the present invention includes the individual isomers and the racemic and non-racemic mixtures of the isomers.

Preferable examples of the compound of the present invention are as follows.

The pyrrolopyrimidine derivative represented by the following formula [II]:



- (wherein R¹ is C₁₋₉alkyl, C₂₋₉alkenyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₉alkyl, di(C₃₋₇cycloalkyl)-C₁₋₉alkyl, C₁₋₆alkoxy-C₁₋₉alkyl, di(C₁₋₆alkoxy)-C₁₋₉alkyl, hydroxy-C₁₋₉alkyl, cyano-C₁₋₉alkyl, carbamoyl-C₁₋₉alkyl, di(C₁₋₆alkyl)amino-C₁₋₉alkyl, aryl, heteroaryl, aryl-C₁₋₉alkyl or heteroaryl-C₁₋₉alkyl, in which said aryl and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, halogen, C₁₋₆haloalkyl, cyano, nitro, -NR^{1a}R^{1b}, where R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₆alkyl and C₁₋₆alkylcarbonyl;

R² is C₁₋₆alkyl or C₁₋₆haloalkyl;

R³ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, benzyl;

R¹⁰ is hydrogen or C₁₋₆alkyl;

- R¹¹ is hydrogen, C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl;

- Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, cyano, haloC₁₋₆alkyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl).

- More preferable are the compound represented by the formula [II], wherein R¹ is C₁₋₉alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, di(C₃₋₇cycloalkyl)-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, di(C₁₋₆alkoxy)-C₁₋₆alkyl, hydroxy-C₁₋₆alkyl, cyano-C₁₋₆alkyl, carbamoyl-C₁₋₆alkyl, di(C₁₋₆alkyl)amino-C₁₋₆alkyl, aryl-C₁₋₆alkyl or

- 10
- heteroaryl-C₁₋₆alkyl; R² is C₁₋₆alkyl; R³ is hydrogen or C₁₋₆alkyl; R¹⁰ is hydrogen or C₁₋₆alkyl; R¹¹ is hydrogen, C₁₋₆alkyl or di(C₁₋₆alkyl)aminoC₁₋₆alkyl; Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with one to three substituents, which are the same or different, selected from the group consisting of
- 5 halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl. More preferable are the compound represented by the formula [II], wherein R¹ is C₁₋₉alkyl, C₃₋₇cycloalkyl, C₃₋
- 10 7cycloalkyl-C₁₋₆alkyl, di(C₃₋₇cycloalkyl)-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, di(C₁₋₆alkoxy)-C₁₋₆alkyl or aryl-C₁₋₆alkyl; R² is C₁₋₆alkyl; R³ is hydrogen or C₁₋₆alkyl; R¹⁰ is hydrogen or C₁₋₆alkyl; R¹¹ is hydrogen or C₁₋₆alkyl; Ar is phenyl which phenyl is unsubstituted or substituted with one to three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋
- 15 3alkylthio, trifluoromethyl and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₃alkyl. More preferable are the compound represented by the formula [III], wherein R¹ is C₁₋₉alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, di(C₃₋₇cycloalkyl)-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, di(C₁₋₆alkoxy)-C₁₋₆alkyl or aryl-C₁₋₆alkyl; R² is C₁₋₃alkyl; R³ is C₁₋₃alkyl; R¹⁰ is
- 20 hydrogen; R¹¹ is hydrogen; Ar is phenyl which phenyl is substituted with 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen or C₁₋₃alkyl.

The preferable bond between X and Y is a double bond.

The preferable R² is C₁₋₆alkyl. More preferable R² is methyl.

- 25 The preferable R³ is C₁₋₆alkyl. More preferable R³ is ethyl.

The preferable R¹⁰ is hydrogen.

The preferable R¹¹ is hydrogen.


- The preferable Ar is phenyl which phenyl is substituted with one to three substituents, which are the same or different, selected from the group consisting of
- 30 halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₃alkyl. The more preferable Ar is phenyl which phenyl is substituted with 2 or 3 substituents, which are the same or different, selected from the group consisting

of halogen or C₁₋₃alkyl.

The compound of the formula [I] can be produced, for example, by the process shown in the following reaction schemes 1-3 (in the following reaction schemes, R¹, R², R³, R¹¹ and Ar are as defined above, L¹ and L² are the same or

- 15 different, selected from the group consisting of chloro, bromo, iodo, methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy or trifluoromethanesulfonyloxy group, L³ is chloro, bromo or iodo, R^a is C₁₋₆alkyl, R^b is C₁₋₆alkyl, R^c is C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl or heteroaryl, R^d is hydrogen or C₁₋₅alkyl).

10 Reaction Scheme 1



Compound (7) and (8), the compounds in the present invention, can be prepared by the method shown in reaction scheme 1. Compound (1) can be transformed to (2) by using a reagent for conversion of amine to guanidine in the presence or absence of a base in an inert solvent. Treatment of compound (2)


- 15 with compound (3) can provide compound (4) in the presence or absence of a base in an inert solvent. Compound (4) can be converted to compound (5) using a halogenating reagent or a sulfonating reagent in the presence or absence of a base in an inert solvent or without using a solvent. Compound (5) can be treated with compound (6) to form compound (7) in the presence or absence of a base in an inert solvent. Treatment of compound (7) with an oxidizing agent in an inert
- 20

12

solvent can give compound (8). When R^3 in compound (7) [or (8)] is hydrogen, treatment of compound (7) [or (8)] with an alkylating reagent in the presence or absence of a base in an inert solvent can provide the N-alkylated compound ($R^3 = C_{1-6}alkyl$).

- 5 Herein, the reagent for conversion of amine to guanidine includes, for example, cyanamide, S-alkylthiuronium salt and its derivatives, aminoiminosulfonic acids, 3,5-dimethylpyrazole-1-carboxamidine nitrate, pyrazole-1-carboxamidine hydrochloride and the like. The base includes, for example, amines such as triethylamine, N,N-diisopropylethylamine, pyridine, N,N-dimethylaniline, N,N-diethylaniline and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; metal amides such as sodium amide, lithium diisopropylamide and the like; and Grignard reagents such as methyl magnesium bromide and the like. The halogenating reagent includes, for example, phosphoryl chloride, phosphoryl bromide, phosphorous pentachloride, phosphorous trichloride, phosphorous pentabromide, phosphorous tribromide, thionyl chloride, thionyl bromide, oxalyl chloride, oxalyl bromide and the like. The sulfonating reagent includes, for example, p-toluenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonic anhydride, methanesulfonic anhydride, trifluoromethanesulfonic anhydride, N-phenylbis(trifluoromethanesulfonimide) and the like. The oxidizing agent includes, for example, manganese dioxide, potassium permanganate, palladium and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methylethylketone and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.


Reaction Scheme 2



- Compound (15), the compound in the present invention, can be prepared by the method shown in reaction scheme 2. Compound (2), synthesized in the same manner as shown in reaction scheme 1, can be converted to compound (10) by reacting with compound (9) in the presence or absence of a base in an inert solvent. Treatment of compound (10) with a halogenating reagent or a sulfonating reagent in the presence or absence of a base in an inert solvent or without using a solvent can provide compound (11). Compound (11) can be reacted with compound (12) in the presence or absence of a base in an inert solvent to form compound (13). Introduction of an iodine atom on the pyrimidine ring of compound (13) can be carried out in an inert solvent by using a conventional reagent for introducing an iodine atom such as iodine, iodine monochloride or the like. Compound (14) can be converted to compound (15) using a palladium catalyst, such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0) or the like, under a carbon monoxide atmosphere in the presence or absence of a base and a ligand in an inert solvent. Herein, the base includes, for example, amines such as triethylamine, N,N-diisopropylethylamine, pyridine, N,N-dimethylaniline, N,N-diethylaniline and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-

butoxide and the like; metal amides such as sodium amide, lithium diisopropylamide and the like; and Grignard reagents such as methyl magnesium bromide and the like. The halogenating reagent includes, for example, phosphoryl chloride, phosphoryl bromide, phosphorous pentachloride, phosphorous trichloride, 5 phosphorous pentabromide, phosphorous tribromide, thionyl chloride, thionyl bromide, oxalyl chloride, oxalyl bromide and the like. The sulfonating reagent includes, for example, p-toluenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonic anhydride, methansulfonic anhydride, trifluoromethanesulfonic anhydride, N-phenylbis(trifluoromethanesulfonimide) and the like. The ligand 10 includes, for example, triphenylphosphine, 1,3-bis(diphenylphosphono)propane and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; esters such as ethyl acetate, 15 ethyl formate and the like; ketones such as acetone, methylethylketone and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.

Reaction Scheme 3



Compound (19), (21), (23), (25), (26), (28), (29), (30), (32), (34), (35), (36), (37), (38) and (39), the compounds in the present invention, can be prepared by the method shown in reaction scheme 3. Compound (2) can be prepared in the same manner as shown in reaction scheme 1. Compound (17) was given by

16

reacting compound (2) with compound (16) in the presence or absence of a base in an inert solvent. Preparation of compound (17) from compound (1) may be performed in one pot continuously. Conversion of compound (17) to compound (18) can be carried out in the same method for the conversion of compound (4) to compound (5) in reaction scheme 1. Treatment of compound (18) with amine (6) in the presence or absence of a base in an inert solvent can provide compound (19). Compound (19) can be transformed to compound (21) by treatment with a base and an alkylating reagent (20) in an inert solvent. Reacting compound (19) with aldehyde (22) in the presence of a base in an inert solvent gave an alkylidene compound (23). Compound (25) can be provided by acylation of compound (19) with isocyanate (24) in the presence of base in an inert solvent. Reduction of a carbonyl group in compound (19) with a reducing agent in an inert solvent can provide compound (26). Compound (28) can be produced by Mannich reaction of compound (26) using an amine (27) and formaldehyde. Conversion of compound (19) to oxime (29) can be performed by reacting compound (19) with a nitrite derivative in the presence or absence of an acid in an inert solvent. Following reduction of the oxime group in compound (29) with a reducing agent in an inert solvent can give compound (30). Acylation of the amino group in compound (30) by using an acylating agent (31) in an inert solvent can give compound (32). Urea derivatives (34) can be produced by reacting compound (30) with an isocyanate (33) in an inert solvent. Reacting a mixture of compound (30) and an aldehyde (22) in the presence of a catalyst for hydrogenation under hydrogen atmosphere or in the presence of a reducing agent in an inert solvent can provide compound (35). Compound (36) can be provided by oxidation of compound (19) with an oxidizing agent in an inert solvent. Treatment of compound (36) with a Grignard reagent or alkyl lithium in an inert solvent can give compound (37). Reduction of compound (37) with a reducing agent in an inert solvent can provide compound (38) and/or compound (39).

Herein, the base includes, for example, amines such as triethylamine, N,N-diisopropylethylamine, pyridine 1,8-diazabicyclo[5.4.0]undec-7-ene and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogen carbonate, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such

as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; metal amides such as sodium amide, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane, potassium hexamethyldisilazane and the like. The acid includes, for example, includes

5 inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid and the like; organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, *p*-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid,

10 glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid and the like. The reducing agent includes, for example, lithium borohydride, sodium borohydride, calcium borohydride, lithium triethylborohydride, lithium tri-sec-butylborohydride, potassium tri-sec-butylborohydride, zinc borohydride, borane, lithium trimethoxyborohydride,

15 lithium triacetoxyborohydride, tetramethylammonium borohydride, lithium aluminum hydride, sodium aluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, diisobutylaluminum hydride, trichlorosilane and the like. The oxidizing agent includes, for example, manganese dioxide, potassium permanganate, palladium and the like. The catalyst for hydrogenation

20 includes, for example, palladium, nickel and the like. The Grignard reagent includes, for example, methylmagnesium iodide, methylmagnesium bromide, methylmagnesium chloride, ethylmagnesium bromide, ethylmagnesium chloride. The alkyl lithium includes, for example, methyl lithium, ethyl lithium, butyl lithium and the like. The nitrite derivative includes, for example, nitrite salts such as

25 sodium nitrite, potassium nitrite and the like; organic nitrite derivatives such as butyl nitrite, isobutyl nitrite, isoamyl nitrite and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene

30 and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methyl ethyl ketone and the like; amides such as *N,N*-dimethylformamide, *N*-methylpyrrolidone, *N,N*-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of

solvents selected from these inert solvents.

The compound of the present invention can be converted to a salt with an acid in an inert solvent. The acid includes inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid and the like; organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, *p*-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; amides such as *N,N*-dimethylformamide, *N*-methylpyrrolidone, *N,N*-dimethylacetamide and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methylethylketone and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.


The compound of the present invention is useful as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved. For this purpose, the compound of the present invention can be formulated into tablets, pills, capsules, granules, powders, solutions, emulsions, suspensions, injections and the like by a conventional preparation technique by adding conventional fillers, binders, disintegrators, pH-adjusting agents, solvents, etc.

The compound of the present invention can be administered to an adult patient in a dose of 0.1 to 500 mg per day in one portion or several portions orally or parenterally. The dose can be properly increased or decreased depending on the kind of a disease and the age, body weight and symptom of a patient.

PREFERRED EMBODIMENTS OF THE INVENTION

The present invention is concretely explained with reference to the following examples and a test example, but is not limited thereto.

Reference example 1



Synthesis of 2-(2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine

- 5 (Step 1) In a flask, equipped with a Dean Stark apparatus, a mixture of 2-bromo-4-isopropyl aniline (50 g) and cyanamide (39 g) in ethyl acetate (850 ml) and ethanol (110 ml) was stirred at room temperature. A solution of 1M HCl in ether was added and the reaction mixture was stirred for 1 h. The ether was distilled and the reaction mixture was stirred and refluxed overnight. The
- 10 reaction mixture was cooled to room temperature and diluted with ether (1000 ml) to give a solid. The solid was filtered off, washed with acetonitrile and dried to give 40 g of N-(2-bromo-4-isopropyl-phenyl)-guanidine hydrochloride. The filtrate was concentrated under reduced pressure and the residue was crystallized from acetonitrile to provide a second fraction (8 g) of the product.
- 15 (Step 2) A mixture of N-(2-bromo-4-isopropyl-phenyl)-guanidine hydrochloride (48 g), 2-acetylbutyrolactone (30 g) and triethylamine (33 g) in ethanol (170 ml) was stirred and refluxed overnight. The solvent was evaporated and the residue purified by a silica gel column chromatography (eluent: dichloromethane/ammonia 7M in methanol = 95 : 5) to give 2-(2-bromo-4-
- 20 isopropyl-phenylamino)-5-(2-hydroxy-ethyl)-6-methyl-3H-pyrimidin-4-one (25 g)

as a solid.

(Step 3) A mixture of 2-(2-bromo-4-isopropyl-phenylamino)-5-(2-hydroxy-ethyl)-6-methyl-3H-pyrimidin-4-one (23.5 g) and phosphorus oxychloride (300ml) was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, washed with water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and the solvent was evaporated. The residue was purified by a silica gel column chromatography (eluent: dichloromethane = 100) to give (2-bromo-4-isopropyl-phenyl)-[4-chloro-5-(2-chloro-ethyl)-6-methyl-pyrimidin-2-yl]-amine (22 g) as a solid.

(Step 4) A mixture of (2-bromo-4-isopropyl-phenyl)-[4-chloro-5-(2-chloro-ethyl)-6-methyl-pyrimidin-2-yl]-amine (6 g) and 2-methoxyethylamine (1.5 g) in dioxane (50 ml) was stirred at 120°C overnight. The solvent was evaporated and the residue was purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 97 : 3) to give (2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2-yl]-amine (3.6 g).

Reference example 2



Synthesis of (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(2-methoxy-ethyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2-yl]-amine


A mixture of (2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2-yl]-amine (0.6 g), iodoethane (0.3 g) and sodium hydride (0.3 g) in tetrahydrofuran (20 ml) was stirred at 60°C for 4 h. Ethyl acetate (40 ml) and a solution of sodium hydroxide 0.5M (40 ml)

21

were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, separated, dried over magnesium sulfate, filtered and the solvent was evaporated. The residue was purified by a silica gel column chromatography (eluent:

- 5 dichloromethane/methanol = 97 : 3) to give (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(2-methoxy-ethyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (0.46 g).

Example 1




- 10 Synthesis of (2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (1-010)

A mixture of (2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2-yl]-amine (1.7 g) and manganese(IV) oxide (1.5 g) in dioxane (25 ml) was stirred and refluxed for 4 h.

- 15 The reaction mixture was cooled and filtered over decalite. The filtrate was concentrated under reduced pressure and purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 99 : 1) to give (2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (0.31 g).


Example 2



Synthesis of (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (1-003)

- A mixture of (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(1-ethyl-propyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (0.4 g) and manganese(IV) oxide (0.4 g) in dioxane (10 ml) was stirred and refluxed for 3 h. The reaction mixture was cooled and filtered over decalite. The filtrate was concentrated under reduced pressure and purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 99 : 1) to give (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (0.37 g).

Example 3




Synthesis of (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(2-methoxy-ethyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (1-002)

- A mixture of (2-bromo-4-isopropyl-phenyl)-[7-(2-methoxy-ethyl)-4-

23

methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (0.9 g), iodoethane (0.4 g) and sodium hydride (0.4 g) in tetrahydrofuran (20 ml) was stirred at 60°C for 4 h. Ethyl acetate (50 ml) and a solution of sodium hydroxide 0.5M (50 ml) were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, separated, dried over magnesium sulfate, filtered and the solvent was evaporated. The residue was purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 98 : 2) to give (2-bromo-4-isopropyl-phenyl)-ethyl-[7-(2-methoxy-ethyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-amine (0.32 g).

10 Example 4



Synthesis of 7-(1-ethyl-propyl)-4-methyl-2-(2,4,6-trimethyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione (4-002)

(Step 1) is analogous to (Reference example 1, step 1).

(Step 2) A mixture of N-(2,4,6-trimethyl-phenyl)-guanidine hydrochloride (14.8 g), ethyl acetoacetate (39 g) and potassium carbonate (14 g) in ethanol (300 ml) was stirred and refluxed for 16 h. The solvent was evaporated and the residue purified by a silica gel column chromatography (eluent:

dichloromethane/methanol = 98 : 2). The product was crystallized from hexane, filtered and dried to provide 6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyrimidine-4-ol (15 g).

(Step 3) A mixture of 6-methyl-2-(2,4,6-trimethyl-phenylamino)-pyrimidine-4-ol (15 g) and phosphorus oxychloride (200 ml) was stirred and refluxed for 16 h. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane. Water was added and the mixture was alkalified with potassium carbonate. The organic layer was washed with water, dried over magnesium sulfate, filtered and evaporated. The residue was purified by a silica gel column chromatography (eluent: dichloromethane = 100) to give (4-chloro-6-methyl-pyrimidine-2-yl)-(2,4,6-trimethyl-phenyl)-amine (11g).

(Step 4) A mixture of (4-chloro-6-methyl-pyrimidine-2-yl)-(2,4,6-trimethyl-phenyl)-amine (7.5 g), 3-ethyl-propylamine (3.5 g) and potassium carbonate (3.5 g) in acetonitrile was stirred at 125°C for 2 days. The solvent was evaporated and the residue was dissolved in water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by a silica gel column chromatography (eluent: dichloromethane/7M ammonia in methanol = 98 : 2). The product was crystallized from isopropyl ether, filtered and dried to give N⁴-(1-ethyl-propyl)-6-methyl-N²-(2,4,6-trimethyl-phenyl)-pyrimidine-2,4-diamine (3.1 g).


(Step 5) To a solution of N⁴-(1-ethyl-propyl)-6-methyl-N²-(2,4,6-trimethyl-phenyl)-pyrimidine-2,4-diamine (3.1 g) in methanol (30 ml) at room temperature was added dropwise a 1M solution of iodine monochloride in dichloromethane (10 ml). The reaction mixture was stirred for 1 h and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol = 98 : 2), crystallized from isopropyl ether, filtered and dried to provide N⁴-(1-ethyl-propyl)-5-iodo-6-

25

methyl-N²-(2,4,6-trimethyl-phenyl)-pyrimidine-2,4-diamine (2.6 g).

- (Step 6) A mixture of N⁴-(1-ethyl-propyl)-5-iodo-6-methyl-N²-(2,4,6-trimethyl-phenyl)-pyrimidine-2,4-diamine (0.5 g), palladium(II) acetate (0.02 g), 1,3-bis(diphenylphosphino)propane (0.08 g) and triethylamine (1 g) in tetrahydrofuran (50 ml) was stirred under 60 atmosphere CO pressure, at 75°C for 16 h. The solvent was evaporated and the residue was purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 95 : 5) to give 7-(1-ethyl-propyl)-4-methyl-2-(2,4,6-trimethyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione (0.12 g).

10 Example 5



Synthesis of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione (4-001)

- (Step 1 and step 2) A mixture of ethyl-(2,4,6-trimethyl-phenyl)-amine (50 g) and cyanamide (21 g) in N-methylpyrrolidone (50 ml) was stirred at 150°C for 1 h. The reaction mixture was cooled to room temperature. Ethanol (500 ml),

ethyl acetoacetate (65 g) and potassium carbonate (37 g) were added and the mixture was stirred and refluxed for 16 h. The solvent was evaporated and the residue was dissolved in water and extracted with ethyl acetate (2x). The combined organic layers were washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was crystallized from isopropyl ether, filtered and dried to provide 2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-6-methyl-pyrimidin-4-ol (29 g). The filtrate was concentrated under reduced pressure and purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give a second fraction of the product (7.7 g).

- 10 (Step 3) A mixture of 2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-6-methyl-pyrimidin-4-ol (2.7 g) and N,N-diisopropylethylamine (1.6 g) in dichloromethane (100 ml) was stirred under nitrogen at 0°C. Triflic anhydride (3.4 g) was added dropwise. The reaction mixture was brought to room temperature and stirred for 1 h. Water was added and the organic layer was dried over magnesium sulfate, 15 filtered and evaporated to give trifluoro-methanesulfonic acid 2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-6-methyl-pyrimidin-4-yl ester (4.1 g).

(Step 4) is analogous to (example 4, step 4).

(Step 5) is analogous to (example 4, step 5).


- (Step 6) A mixture of N²-ethyl-N⁴-(1-ethyl-propyl)-5-iodo-6-methyl-N²-20 (2,4,6-trimethyl-phenyl)-pyrimidine-2,4-diamine (0.5 g), palladium(II) acetate (0.02 g), 1,3-bis(diphenylphosphino)propane (0.08 g) and diethylamine (25 ml) in tetrahydrofuran (50 ml) was stirred under 60 atmosphere CO pressure, at 75°C for 16 h. The solvent was evaporated and the residue was purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 95 : 5) to give N,N-diethyl-2-{4-(1-ethyl-propylamino)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-6-methyl-pyrimidin-5-yl}-2-oxo-acetamide (0.2 g). 25

(Step 7) N,N-diethyl-2-{4-(1-ethyl-propylamino)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-6-methyl-pyrimidin-5-yl}-2-oxo-acetamide (0.05 g) and

27

a solution of 6M hydrochloric acid in 2-propanol (1 ml) were stirred at 150°C for 30 minutes. The product was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione (0.006 g).

Example 6



Synthesis of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (3-001)


(Step 1 and step 2) A mixture of ethyl-(2,4,6-trimethyl-phenyl)-amine (50 g) and cyanamide (21 g) in N-methylpyrrolidone (50 ml) was stirred at 150°C for 1 h. The reaction mixture was cooled to room temperature. Ethanol (1000 ml), diethyl acetylsuccinate (65 g) and potassium carbonate (74 g) were added and the mixture was stirred and refluxed for 16 h. Diethyl acetylsuccinate (65 g) was added a second time and the reaction mixture was stirred and refluxed for 24 h. A solution of 6M hydrochloric acid in 2-propanol was added and the mixture was stirred at 60°C for 24 h. The solvent was evaporated and water was added. The mixture was alkalinified with a solution of potassium carbonate and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 95 : 5) to provide {2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-hydroxy-6-methyl-pyrimidin-5-yl}-

acetic acid ethyl ester (78 g).

(Step 3) is analogous to (example 5, step 3)

(Step 4) A mixture of {2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-6-trifluoromethanesulfonyloxy-pyrimidin-5-yl}-acetic acid ethyl ester (10 g), 1-ethyl-propylamine (4 g) and potassium carbonate (4 g) in acetonitrile (100 ml) was stirred at 125°C for 72 h. The solvent was evaporated and the residue was dissolved in water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate and evaporated to give 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (8 g).

Example 7



Synthesis of 5-ethyl-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-5-hydroxy-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (3-020)


(Step 1) A mixture of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.6 g) and manganese(IV) oxide (0.5 g) in dichloromethane (2 ml) was stirred at room temperature for 16 h. The reaction mixture was filtered over decalite and the filtrate was concentrated under reduced pressure to give 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione (0.1 g).

(Step 2) A solution of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-

29

phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione (0.15 g) in tetrahydrofuran (1.5 ml) under nitrogen was stirred at -20°C . 1 M ethylmagnesium bromide in tetrahydrofuran (0.5 ml) was added. The reaction mixture was brought to room temperature and stirred for 1 h. A solution of ammonium chloride (1 ml) was added and the product was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give 5-ethyl-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-5-hydroxy-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.034 g).

Example 8



Synthesis of ethyl-[7-(1-ethyl-propyl)-4,5-dimethyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (2-001) and ethyl-[7-(1-ethyl-propyl)-4,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (1-015)

7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-5-hydroxy-4,5-dimethyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.8 g), prepared in the similar method as example 7, in tetrahydrofuran (20 ml) was stirred at 0°C under nitrogen. Borane-tetrahydrofuran complex, 1M solution in tetrahydrofuran (14 ml) was added and the reaction mixture was stirred for 16 h. The solvent was evaporated, water and potassium carbonate were added and the product was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give ethyl-[7-(1-ethyl-propyl)-4,5-dimethyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (0.035 g) and ethyl-

30

[7-(1-ethyl-propyl)-4,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]- (2,4,6-trimethyl-phenyl)-amine (0.011 g).


Example 9



Synthesis of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-
5 4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione 5-oxime (6-001)

A solution of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (1.3 g) in acetic acid (20 ml) was stirred at room temperature. Sodium nitrite (0.5 g) was added and 3 drops of water were added. The reaction mixture was stirred for 1 h, poured out
10 into water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and evaporated to provide 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione 5-oxime (1.4 g) as a mixture of the geometric isomers.

Example 10



15 Synthesis of N-{7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl}-propionamide (3-005)


(Step 1) 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione 5-oxime (0.5 g) was hydrogenated

31

with Raney Nickel in tetrahydrofuran (50 ml). The reaction mixture was filtered over decalite and the filtrate was concentrated under reduced pressure to give 5-amino-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.5 g).

- 5 (Step 2) A mixture of 5-amino-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.15 g), propionyl chloride (0.055 g) and triethylamine (0.1 g) in dichloromethane (2 ml) was stirred at room temperature for 16 h. Water was added and the product was extracted with dichloromethane. The organic layer was dried over
- 10 magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give N-{7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl}-propionamide (0.034 g).

15 Example 11




Synthesis of 1-{7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl}-3-isopropyl-urea (3-007)

- A mixture of 5-amino-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.15 g), 2-isocyanato-propane (0.042 g), dimethylaminopropylamine (cat.) in dioxane (3 ml) was stirred at room temperature for 16 h. Water was added and the product was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue
- 25 was purified by a reversed phase column chromatography (eluent: ammonium

32

acetate/acetonitrile) to give 1-{7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl}-3-isopropyl-urea (0.015 g).

Example 12



- 5 Synthesis of 5-dimethylamino-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (3-010)

- A mixture of 5-amino-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.1 g),
 10 paraformaldehyde (0.1 g), palladium on activated carbon, 10 % (0.1 g) and thiophene 4% in diisopropylether (0.1 ml) in methanol (40 ml) was hydrogenated at 50°C. The reaction mixture was filtered over decalite and the filtrate was concentrated under reduced pressure. Water was added and the product was extracted with dichloromethane. The organic layer was dried over magnesium
 15 sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give 5-dimethylamino-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.013 g).

- 20 Example 13



Synthesis of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4,5,5-trimethyl-5,7dihydro-pyrrolo[2,3-d]pyrimidin-6-one (3-009)

A mixture of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.15 g) and sodium hydride 5 50% (0.04 g) in tetrahydrofuran was stirred at room temperature for 15 minutes. Iodomethane (0.12 g) was added and the reaction mixture was stirred for 1 h. Water was added and the product was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column 10 chromatography (eluent: ammonium acetate/acetonitrile) to give 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4,5,5-trimethyl-5,7dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.004 g).

Example 14



Synthesis of 5,5-diethyl-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (3-018) 15

A mixture of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.015 g) and sodium bis(trimethylsilyl)amide in dioxane (2 ml) was stirred at room temperature for 15 minutes under nitrogen. Bromoethane (0.087 g) was added and the reaction 20 mixture was stirred at 60°C for 1 h. Water was added and the product was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give 5,5-diethyl-7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one 25 (0.018 g).


Example 15



Synthesis of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-
5-isobutylidene-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (5-001)

- A mixture of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-
4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.15 g), isobutyraldehyde
(0.057 g) and piperidine in dioxane (1.5 ml) was stirred at 65°C for 16 h. Water
was added and the product was extracted with dichloromethane. The organic
layer was dried over magnesium sulfate, filtered and concentrated under reduced
pressure. The residue was purified by a reversed phase column chromatography
(eluent: ammonium acetate/acetonitrile) to give 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-
trimethyl-phenyl)-amino]-5-isobutylidene-4-methyl-5,7-dihydro-pyrrolo[2,3-
d]pyrimidin-6-one (0.071 g) as a mixture of the geometric isomers.

Example 16




- Synthesis of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-
4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-carboxylic acid
isopropylamide (3-022)

- A mixture of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-
4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (0.15 g), 2-isocyanato propane
(0.042 g) and sodium bis(trimethylsilyl)amide in dioxane (2 ml) was stirred at 85°C
for 16 h. Water was added and the product was extracted with dichloromethane.
The organic layer was dried over magnesium sulfate, filtered and concentrated

35

under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-carboxylic acid isopropylamide (0.114 g).

5 Example 17




Synthesis of ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (1-008)

- (Step 1) A solution of 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (1 g) in tetrahydrofuran (20 ml) was stirred at 0°C under nitrogen. Borane-tetrahydrofuran complex, 1M solution in tetrahydrofuran (12.5 ml) was added dropwise and the reaction mixture was stirred for 2 h at room temperature. Methanol/acetic acid 1:1 was added and the solvent was evaporated. The residue was dissolved in water, alkalinized with potassium carbonate and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to provide a mixture of ethyl-[7-(1-ethyl-propyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (60%) and ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (32 %) (1 g). The residue was used without further purification.

(Step 2) A mixture of ethyl-[7-(1-ethyl-propyl)-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (60%) and ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (32 %) (1 g) and manganese(IV) oxide (5 g) in dichloromethane were stirred at room temperature for 76 h. The reaction mixture was filtered over decalite and the filtrate was concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (eluent: dichloromethane/methanol = 98 : 2) to give ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (0.119 g) and 7-(1-ethyl-propyl)-2-[ethyl-(2,4,6-trimethyl-phenyl)-amino]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5,6-dione.


Example 18















Synthesis of [5-dimethylaminomethyl-7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-ethyl-(2,4,6-trimethyl-phenyl)-amine (1-014)

Formaldehyde, 37wt% solution (0.5 ml) was stirred at room temperature. Dimethylamine in water was added and the reaction mixture was stirred for 15 minutes. Ethyl-[7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(2,4,6-trimethyl-phenyl)-amine (0.05 g) in methanol (0.5 ml) was added and the reaction mixture was stirred at 60°C for 3 h. Water was added and the product was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by a reversed phase column chromatography (eluent: ammonium acetate/acetonitrile) to give [5-dimethylaminomethyl-7-(1-ethyl-propyl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-ethyl-(2,4,6-trimethyl-phenyl)-amine (0.015 g).

Tables 1-6 list the compounds obtained in Examples 1-20 and compounds obtained by the similar procedure as in Examples 1-20.

Table 1^{*1}


Com. No.	Ex. No.	R ¹	R ³	R ¹⁰	R ¹¹	Ar	MS	R.T. (min)
1-001	3		Et	H	H		ESI 463 (M ⁺ +1)	14.0
1-002	3		Et	H	H		ESI 431 (M ⁺ +1)	7.3
1-003	2		Et	H	H		EI 442 (M ⁺)	19.4
1-004	2		Et	H	H		ESI 481 (M ⁺ +Na)	12.4
1-005	3		Et	H	H		ESI 411 (M ⁺ +1)	9.9
1-006	3		Et	H	H		EI 378 (M ⁺)	6.0
1-007	2		Et	H	H		EI 390 (M ⁺)	14.9
1-008	17		Et	H	H		ESI 365 (M ⁺ +1)	19.2
1-009	1		H	H	H		ESI 435 (M ⁺ +1)	11.0

1-O10	1		H	H	H		ESI 403 ($M^+ + 1$)	6.2
1-O11	1		Et	H	H		ESI 481 ($M^+ + Na$)	11.8
1-O12	1		H	H	H		ESI 383 ($M^+ + 1$)	8.3
1-O13	1		H	H	H		EI 350 (M^+)	5.2
1-O14	18		Et	H	CH_2NMe_2		ESI 444 ($M^+ + Na$)	10.2
1-O15	8		Et	H	Me		ESI 401 ($M^+ + Na$)	20.5

*1: Com. No. = compound number, Ex. No. = example number, MS = mass spectrum, ESI = electrospray ionization, EI = electron ionization, Me = methyl, Et = ethyl, R.T. = retention time on HPLC, HPLC conditions: Capcell Pak UG120, 4.6 mm \times 150 mm, Shiseido; Flow rate: 1.0 ml/min; mobile phase: acetonitrile / 0.05M ammonium acetate aqueous solution (80 : 20), pH of the solvent was adjusted to 7.4 with aqueous ammonia or acetic acid.

39


Table 2*1





































Com. No.	Ex. No.	R ¹	R ³	R ⁴	R ⁵	R ⁶	R ⁷	Ar	MS	R.T. (min)
2-001	8		Et	H	H	Me	H		ESI 381 (M ⁺ +1)	3.6























*1: Com. No. = compound number, Ex. No. = example number, Me = methyl, Et = ethyl, MS = mass spectrum, ESI = electrospray ionization, EI = electron ionization, R.T. = retention time on HPLC, HPLC conditions: Capcell Pak UG120, 4.6 mm × 150 mm, Shiseido; Flow rate: 1.0 ml/min; mobile phase: acetonitrile / 0.05M ammonium acetate aqueous solution (80 : 20), pH of the solvent was adjusted to 7.4 with aqueous ammonia or acetic acid.

Table 3*1



Com. No.	Ex. No.	R ¹	R ³	R ⁶	R ⁷	Ar	MS	R.T. (min)
3-001	6		Et	H	H		EI 380 (M ⁺)	9.9
3-002*2	10		Et		H		ESI 480 (M ⁺ +1)	4.6


3-003 ²	10		Et		H		ESI 466 (M ⁺ +1)	4.4
3-004 ²	10		Et		H		ESI 464 (M ⁺ +1)	4.3
3-005 ²	10		Et		H		ESI 452 (M ⁺ +1)	4.3
3-006 ²	10		Et		H		ESI 490 (M ⁺ +1)	4.2
3-007	11		Et		H		ESI 503 (M ⁺ +Na)	5.9
3-008	11		Et		H		ESI 503 (M ⁺ +Na)	5.9
3-009	13		Et	Me	Me		EI 408 (M ⁺ +1)	17.1
3-010	12		Et		H		EI 423 (M ⁺)	17.4
3-011	10		Et		H		ESI 460 (M ⁺ +Na)	5.5
3-012	7		Et	OH	Me		ESI 433 (M ⁺ +Na)	7.6
3-013	7		Et	OH			ESI 445 (M ⁺ +Na)	8.5
3-014	7		Et	OH			ESI 443 (M ⁺ +Na)	7.9

3-015	7		Et	OH			ESI 475 ($M^+ + Na$)	12.4
3-016	7		Et	OH			ESI 459 ($M^+ + Na$)	10.7
3-017	7		Et	OH			ESI 459 ($M^+ + Na$)	9.3
3-018	14		Et	Et	Et		ESI 437 ($M^+ + 1$)	24.2
3-019	14		Et				ESI 483 ($M^+ + Na$)	23.7
3-020	7		Et	OH	Et		ESI 447 ($M^+ + Na$)	8.7
3-021	14		Et	$-CH_2CH_2-$			ESI 429 ($M^+ + Na$)	21.6
3-022	16		Et		H		ESI 488 ($M^+ + Na$)	5.8

*1: Com. No. = compound number, Ex. No. = example number, Me = methyl, Et = ethyl, MS = mass spectrum, ESI = electrospray ionization, EI = electron ionization, R.T. = retention time on HPLC, HPLC conditions: Capcell Pak UG120, 4.6 mm \times 150 mm, Shiseido; Flow rate: 1.0 ml/min; mobile phase: acetonitrile / 0.05M ammonium acetate aqueous solution (80 : 20), pH of the solvent was adjusted to 7.4 with aqueous ammonia or acetic acid.

*2: HPLC conditions: X Terra MS C18 2.5 μ m, 4.6 mm \times 50 mm; Waters; Flow rate: 1.2 ml/min; mobile phase: A = 0.5 % ammonium acetate in H₂O/CH₃CN (90/10); B = methanol; C = acetonitrile; gradient: start: 90% A + 10% B; end: 10% A + 90% C

Table 4*1




Com. No.	Ex. No.	R ¹	R ³	Ar	MS	R.T. (min)
4-001	5		Et		ESI 417 (M ⁺ +Na)	7.9, 9.6
4-002	4		H		ESI 389 (M ⁺ +Na)	4.1

*1: Com. No. = compound number, Ex. No. = example number, Me = methyl, Et = ethyl, MS = mass spectrum, ESI = electrospray ionization, R.T. = retention time on HPLC, HPLC conditions: Capcell Pak UG120, 4.6 mm × 150 mm, Shiseido; Flow rate: 1.0 ml/min; mobile phase: acetonitrile / 0.05M ammonium acetate aqueous solution (80 : 20), pH of the solvent was adjusted to 7.4 with aqueous ammonia or acetic acid.


43

Table 5*1



Com. No.	Ex. No.	R^1	R^3	R^9	Ar	MS	R.T. (min)
5-001	15		Et			ESI 457 ($M^+ + Na$)	31.8, 42.2
5-002	15		Et			ESI 481 ($M^+ + Na$)	21.6, 38.1
5-003	15		Et			ESI 455 ($M^+ + Na$)	23.5, 26.2
5-004	15		Et			ESI 492 ($M^+ + Na$)	13.1, 16.7
5-005	15		Et			ESI 495 ($M^+ + Na$)	7.4, 9.4

*1: Com. No. = compound number, Ex. No. = example number, Me = methyl, Et = ethyl, MS = mass spectrum, ESI = electrospray ionization, R.T. = retention time on HPLC, HPLC conditions: Capcell Pak UG120, 4.6 mm \times 150 mm, Shiseido; Flow rate: 1.0 ml/min; mobile phase: acetonitrile / 0.05M ammonium acetate aqueous solution (80 : 20), pH of the solvent was adjusted to 7.4 with aqueous ammonia or acetic acid.

Table 6^{*1}

Com. No.	Ex. No.	R ¹	R ³	R ⁸	Ar	MS	R.T. (min)
6-001	9		Et	H		ESI 432 (M ⁺ +Na)	7.8, 10.0

*1: Com. No. = compound number, Ex. No. = example number, Me = methyl, Et = ethyl, MS = mass spectrum, ESI = electrospray ionization, R.T. = retention time on HPLC, HPLC conditions: Capcell Pak UG120, 4.6 mm × 150 mm, Shiseido; Flow rate: 1.0 ml/min; mobile phase: acetonitrile / 0.05M ammonium acetate aqueous solution (80 : 20), pH of the solvent was adjusted to 7.4 with aqueous ammonia or acetic acid.

Test Example [CRF receptor binding test]

Monkey amygdala membranes were used as a receptor preparation.

¹²⁵I-CRF was used as ¹²⁵I-labeled ligand.

Binding reaction using the ¹²⁵I-labeled ligand was carried out by the

- 5 following method described in The Journal of Neuroscience, 7, 88 (1987).

Preparation of receptor membranes:

Monkey amygdala was homogenized in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl₂, 2 mM EDTA and centrifuged at 48,000 × g for 20 min, and the precipitate was washed once with Tris-HCl buffer. The washed

- 10 precipitate was suspended in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl₂, 2 mM EDTA, 0.1% bovine serum albumin and 100 kallikrein units/ml aprotinin, to obtain a membrane preparation.

CRF receptor binding test:

The membrane preparation (0.3 mg protein/ml), ¹²⁵I-CRF (0.2 nM) and a

45

test drug were reacted at 25°C for 2 h. After completion of the reaction, the reaction mixture was filtered by suction through a glass filter (GF/C) treated with 0.3% polyethylene imine, and the glass filter was washed three times with phosphate-buffered saline containing 0.01% Triton X-100. After the washing, the radioactivity of the filter paper was measured in a gamma counter.

The amount of ^{125}I -CRF bound when the reaction was carried out in the presence of 1 μM CRF was taken as the degree of nonspecific binding of ^{125}I -CRF, and the difference between the total degree of ^{125}I -CRF binding and the degree of nonspecific ^{125}I -CRF binding was taken as the degree of specific ^{125}I -CRF binding.

10 An inhibition curve was obtained by reacting a definite concentration (0.2 nM) of ^{125}I -CRF with various concentrations of each test drug under the conditions described above. A concentration of the test drug at which binding of ^{125}I -CRF is inhibited by 50% (IC_{50}) was determined from the inhibition curve.


15 As a result, it was found that compounds 1-003, 1-004, 1-008 and 1-011 can be exemplified as typical compounds having an IC_{50} value of 200 nM or less.

ADVANTAGEOUS EFFECT OF THE INVENTION

According to the present invention, compounds having a high affinity for CRF receptors have been provided. These compounds are effective against diseases in which CRF is considered to be involved, such as depression, anxiety, 20 Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.

46
CLAIMS

1. A pyrrolopyrimidine derivative represented by the following formula [I]:



(wherein R¹ is C₁₋₉alkyl, C₂₋₉alkenyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₉alkyl, di(C₃₋₇cycloalkyl)-C₁₋₉alkyl, C₁₋₆alkoxy-C₁₋₉alkyl, di(C₁₋₆alkoxy)-C₁₋₉alkyl, hydroxy-C₁₋₉alkyl, cyano-C₁₋₉alkyl, carbamoyl-C₁₋₉alkyl, di(C₁₋₆alkyl)amino-C₁₋₉alkyl, aryl, heteroaryl, aryl-C₁₋₉alkyl or heteroaryl-C₁₋₉alkyl, in which said aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, halogen, C₁₋₆haloalkyl, cyano, nitro, -NR^{1a}R^{1b}, where R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₆alkyl and C₁₋₆alkylcarbonyl;

R² is C₁₋₆alkyl or C₁₋₆haloalkyl;

R³ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, benzyl;

the bond between X and Y is a single bond or a double bond;

wherein (1) when the bond between X and Y is a single bond, X is CR⁴R⁵ or C=O; Y is CR⁶R⁷, C=O, C=N-OR⁸ or C=CH-R⁹; (2) when the bond between X and Y is a double bond, X is CR¹⁰; Y is CR¹¹;

R⁴ and R⁵ are the same or different, and independently are hydrogen or C₁₋₆alkyl;

R⁶ and R⁷ are the same or different, and independently are hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, hydroxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino-C₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₃₋₆cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, C₁₋₆alkylaminocarbonyl or C₁₋₆alkylaminocarbonylamino; or R⁶ and R⁷ are taken together to form C₃₋₆cycloalkyl, with the proviso that not both of CR⁴R⁵ and CR⁶R⁷

are CH₂;

R⁸ is hydrogen or C₁₋₆alkyl;


R⁹ is C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen or C₁₋₆alkyl;

R¹⁰ is hydrogen or C₁₋₆alkyl;

R¹¹ is hydrogen, C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, cyano, C₁₋₆haloalkyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

2. The pyrrolopyrimidine derivative according to claim 1 represented by the following formula [III]:



(wherein R¹ is C₁₋₉alkyl, C₂₋₉alkenyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₉alkyl, di(C₃₋₇cycloalkyl)-C₁₋₉alkyl, C₁₋₆alkoxy-C₁₋₉alkyl, di(C₁₋₆alkoxy)-C₁₋₉alkyl, hydroxy-C₁₋₉alkyl, cyano-C₁₋₉alkyl, carbamoyl-C₁₋₉alkyl, di(C₁₋₆alkyl)amino-C₁₋₉alkyl, aryl, heteroaryl, aryl-C₁₋₉alkyl or heteroaryl-C₁₋₉alkyl, in which said aryl and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, halogen, C₁₋₆haloalkyl, cyano, nitro, -NR^{1a}R^{1b}, where R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋

alkyl and C₁₋₆alkylcarbonyl;

R² is C₁₋₆alkyl or C₁₋₆haloalkyl;

R³ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, benzyl;

R¹⁰ is hydrogen or C₁₋₆alkyl;

R¹¹ is hydrogen, C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, aminosulfonyl, mono(C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl, cyano, haloC₁₋₆alkyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

3. The pyrrolopyrimidine derivative according to claim 2 represented by the formula [II], wherein R¹ is C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, di(C₃₋₇cycloalkyl)-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, di(C₁₋₆alkoxy)-C₁₋₆alkyl, hydroxy-C₁₋₆alkyl, cyano-C₁₋₆alkyl, carbamoyl-C₁₋₆alkyl, di(C₁₋₆alkyl)amino-C₁₋₆alkyl, aryl-C₁₋₆alkyl or heteroaryl-C₁₋₆alkyl; R² is C₁₋₆alkyl; R³ is hydrogen or C₁₋₆alkyl; R¹⁰ is hydrogen or C₁₋₆alkyl; R¹¹ is hydrogen, C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl; Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with one to three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₆alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

4. The pyrrolopyrimidine derivative according to claim 2 represented by the formula [III], wherein R¹ is C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, di(C₃₋₇cycloalkyl)-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, di(C₁₋₆alkoxy)-C₁₋₆alkyl or aryl-C₁₋₆alkyl; R² is C₁₋₆alkyl; R³ is hydrogen or C₁₋₆alkyl; R¹⁰ is hydrogen or C₁₋₆alkyl; R¹¹

is hydrogen or C₁₋₆alkyl; Ar is phenyl which phenyl is unsubstituted or substituted with one to three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl and -N(R¹²)R¹³, wherein R¹² and R¹³ are the same or different, and independently are hydrogen or C₁₋₃alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

5. The pyrrolopyrimidine derivative according to claim 2 represented by the formula [II], wherein R¹ is C₁₋₉alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, di(C₃₋₇cycloalkyl)-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, di(C₁₋₆alkoxy)-C₁₋₆alkyl or aryl-C₁₋₆alkyl; R² is C₁₋₃alkyl; R³ is C₁₋₃alkyl; R¹⁰ is hydrogen; R¹¹ is hydrogen; Ar is phenyl which phenyl is substituted with 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen or C₁₋₃alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

6. An antagonist for CRF receptors, comprising a pyrrolopyrimidine derivative, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 5, as an active ingredient.

7. Use of a pyrrolopyrimidine derivative, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 5, for the manufacture of an antagonist for CRF receptors.

INTERNATIONAL SEARCH REPORT

Int onal Application No
PCT/JP 2005/004266

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94/13676 A (PFIZER INC; CHEN, YUHPYNG, L) 23 June 1994 (1994-06-23) Formula I, page 6, line 7 - page 7, line 2; claim 11 -----	1-7
A	WO 02/088095 A (GLAXO GROUP LIMITED; CAPELLI, ANNA, MARIA; DI FABIO, ROMANO; MARCHIONNI) 7 November 2002 (2002-11-07) Formula I, page 6, line 32 - page 7, line 11; claim 16 -----	1-7
A	WO 02/100863 A (GLAXO GROUP LIMITED; DI FABIO, ROMANO; MARCHIONNI, CHIARA; MICHELI, FA) 19 December 2002 (2002-12-19) Formula I, page 11, line 6 - page 14, line 12; claims 1,8 ----- -/-	1-7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

I later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

27 June 2005

Date of mailing of the international search report

01/07/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Rudolf, M

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/JP2005/004266

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP 2000 086663 A (TAISHO PHARMACEUT CO LTD) 28 March 2000 (2000-03-28) Compounds V, tables IV,V -----	1-7
A	EP 0 976 745 A (TAISHO PHARMACEUTICAL CO. LTD; TAISHO PHARMACEUTICAL CO., LTD) 2 February 2000 (2000-02-02) Formula I, paragraph '0044! -----	1-7
P,X	WO 2004/099209 A (F. HOFFMANN-LA-ROCHE AG; O'YANG, COUNDE; SCHOENFELD, RYAN, CRAIG) 18 November 2004 (2004-11-18) page 5, lines 4-25; claims 1,22,26; table 1 -----	1,6,7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2005/004266

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9413676	A	23-06-1994	AT 177101 T 15-03-1999
			AU 690090 B2 23-04-1998
			AU 5666494 A 04-07-1994
			BR 9307646 A 25-05-1999
			CA 2150016 A1 23-06-1994
			CN 1097758 A ,C 25-01-1995
			CZ 9501584 A3 17-01-1996
			DE 69323768 D1 08-04-1999
			DE 69323768 T2 01-07-1999
			DK 674641 T3 27-09-1999
			EP 0674641 A1 04-10-1995
			ES 2128544 T3 16-05-1999
			FI 935585 A 18-06-1994
			FI 20000343 A 16-02-2000
			GR 3029561 T3 30-06-1999
			HU 70505 A2 30-10-1995
			IL 107897 A 28-01-2001
			IL 119461 A 29-02-2000
			IL 119462 A 29-02-2000
			JP 2895961 B2 31-05-1999
			JP 7509726 T 26-10-1995
			KR 173172 B1 01-02-1999
			NO 952398 A 16-06-1995
			NZ 258690 A 29-01-1997
			PL 309357 A1 02-10-1995
			RU 2124015 C1 27-12-1998
			WO 9413676 A1 23-06-1994
			US 6765008 B1 20-07-2004
			ZA 9309271 A 12-06-1995
WO 02088095	A	07-11-2002	BR 0209267 A 15-06-2004
			CA 2446514 A1 07-11-2002
			CZ 20032946 A3 12-05-2004
			EP 1383747 A1 28-01-2004
			WO 02088095 A1 07-11-2002
			HU 0304054 A2 28-04-2004
			JP 2004528349 T 16-09-2004
			NO 20034836 A 29-10-2003
			PL 366934 A1 07-02-2005
			US 2004176400 A1 09-09-2004
			ZA 200307367 A 21-04-2004
			EP 1395591 A1 10-03-2004
			WO 02100863 A1 19-12-2002
			JP 2004533465 T 04-11-2004
			US 2005054661 A1 10-03-2005
WO 02100863	A	19-12-2002	EP 1395591 A1 10-03-2004
			WO 02100863 A1 19-12-2002
			JP 2004533465 T 04-11-2004
			US 2005054661 A1 10-03-2005
			BR 0209267 A 15-06-2004
			CA 2446514 A1 07-11-2002
			CZ 20032946 A3 12-05-2004
			EP 1383747 A1 28-01-2004
			WO 02088095 A1 07-11-2002
			HU 0304054 A2 28-04-2004
			JP 2004528349 T 16-09-2004
			NO 20034836 A 29-10-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2005/004266

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02100863	A	PL 366934 A1 US 2004176400 A1	07-02-2005 09-09-2004
JP 2000086663	A	28-03-2000	NONE
EP 0976745	A	02-02-2000	AT 247102 T 15-08-2003 AU 733604 B2 17-05-2001 AU 6517598 A 20-10-1998 CA 2285445 A1 01-10-1998 DE 69817172 D1 18-09-2003 DE 69817172 T2 08-04-2004 DK 976745 T3 27-10-2003 EP 0976745 A1 02-02-2000 HK 1027809 A1 12-11-2004 US 6187781 B1 13-02-2001 CN 1257491 A ,C 21-06-2000 ES 2203937 T3 16-04-2004 JP 11228568 A 24-08-1999 WO 9842699 A1 01-10-1998 PT 976745 T 31-12-2003
WO 2004099209	A	18-11-2004	WO 2004099209 A1 18-11-2004 US 2004224964 A1 11-11-2004